-
article
Pemmaraju N, Mead AJ, Somervaille TCP, Palandri F, Koschmieder S, Delage R, Kiladjian JJ, Benton CB, Tantravahi SK, Lavi N, Yeh SP, Gomez Casares MT, Ammatuna E, McDonald AB, Yoon SS, Kirito K, Devos T, Perkins AC, Radinoff A, Sevindik OG, Bogdanovic A, Moskal R, Harb JG, Murray BC, Jiang Q, Chopra AS, Papadopoulos EJ, Potluri J, Passamonti F
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis
Blood
2026.
-
article
Gagnon LL, Duminuco A, Stagno F, Sobas M, Fominykh M, Virchis A, Nicolini FE, Hildt J, Bentley H, Godfrey AL, Shih LY, Chee A, Mead A, Lewandowski K, Sobieralski P, Hannah G, Reyal Y, Cummin T, Piszcz J, Yip K, Frewin R, Narayanan S, Rahman D, Ajayi A, Cervi P, Byrne J, Taylor T, Lebowa W, Pavlu J, Arami S, Ceesay M, Chraniuk D, Delage R, Condorelli A, Santana C, Radia DH, de Lavallade H, Milojkovic D, Harrison C, Harrington P
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes
Leukemia
40 (5), 2026.
-
article
Poullet A, Busque L, Sirhan S, Delage R, Cournoyer G, Chamakhi I, Talbot D, Mollica L, Marceau D, Ethier V, Desjardins P, Olney HJ, Harnois M, Szuber N
Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact-a study of 784 patients from the Quebec MPN research group
Blood Cancer J
15 (1), 2025.
